Last reviewed · How we verify
N4 Pharma UK Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Oral sildenafil | Oral sildenafil | marketed | ||||
| Sublingual sildenafil | Sublingual sildenafil | phase 3 | Phosphodiesterase type 5 inhibitor | PDE5 | Urology |
Therapeutic area mix
- Urology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for N4 Pharma UK Ltd.:
- N4 Pharma UK Ltd. pipeline updates — RSS
- N4 Pharma UK Ltd. pipeline updates — Atom
- N4 Pharma UK Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). N4 Pharma UK Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/n4-pharma-uk-ltd. Accessed 2026-06-10.